Preclinical testing of tandutinib in a transgenic medulloblastoma mouse model

Journal of Pediatric Hematology/Oncology

Volumn 34, Issue 2, 2012, Pages 116-121

  Ohshima Hosoyama, Sachiko ^a   Davare, Monika A ^a   Prajapati, Suresh I ^a   Abraham, Jinu ^a   Lal, Sangeet ^a   Nelon, Laura D ^a   Kilcoyne, Aoife ^a,b   Giles, Francis J ^b   Hanes, Martha A ^c   Rubin, Brian P ^d   Keller, Charles ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

medulloblastoma; platelet derived growth factor receptor; tandutinib; virtual histology

Indexed keywords

CASPASE 3; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN P53; PROTEIN PATCHED 1; TANDUTINIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MEDULLOBLASTOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL SEPARATION; CEREBELLAR NEOPLASMS; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; MEDULLOBLASTOMA; MICE; MICE, TRANSGENIC; PIPERAZINES; QUINAZOLINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84857921740     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3182309fe4     Document Type: Article

References (28)

1. Rutkowski S, Gerber NU, von Hoff K, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy and deferred radiotherapy. Neuro Oncol. 2009;11:201-210.
2. Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2006;24:4202-4208.
3. Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): Long-term results from a prospective, multicentre trial. Lancet Oncol. 2006;7:813-820.
4. Lafay-Cousin L, Strother D. Current treatment approaches for infants with malignant central nervous system tumors. Oncologist. 2009;14:433-444.
5. MacDonald TJ, Brown KM, LaFleur B, et al. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet. 2001;29:143-152.
6. Huber H, Eggert A, Janss AJ, et al. Angiogenic profile of childhood primitive neuroectodermal brain tumours/medulloblastomas. Eur J Cancer. 2001;37:2064-2072.
7. Chopra A, Brown KM, Rood BR, et al. The use of gene expression analysis to gain insights into signaling mechanisms of metastatic medulloblastoma. Pediatr Neurosurg. 2003;39:68-74.
8. Gilbertson RJ. Clifford SC: PDGFRB is overexpressed in metastatic medulloblastoma. Nat Genet. 2003;35:197-198.
9. Andrae J, Molander C, Smits A, et al. Platelet-derived growth factor-B and -C and active alpha-receptors in medulloblastoma cells. Biochem Biophys Res Commun. 2002;296:604-611.
10. Whelan HT. Medulloblastoma cell line. Pediatr Neurol. 1990;6:282.
11. Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008;26: 127-132.
12. Pandey A, Volkots DL, Seroogy JM, et al. Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family. J Med Chem. 2002;45:3772-3793.
13. Kelly LM, Yu JC, Boulton CL, et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell. 2002;1:421-432.
14. DeAngelo DJ, Stone RM, Heaney ML, et al. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: Safety, pharmacokinetics, and pharmacodynamics. Blood. 2006;108:3674-3681.
15. Supko JG, Grossman SA, Peereboom DM, et al. Feasibility and phase I trial of tandutinib in patients with recurrent glioblastoma. J Clin Oncol (Meeting Abstracts). 2009; 27:2039.
16. Taniguchi E, Nishijo K, McCleish AT, et al. PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma. Oncogene. 2008;27:6550-6560.
17. Prajapati SI, Kilcoyne A, Samano AK, et al. MicroCT-based virtual histology evaluation of preclinical medulloblastoma. Mol Imaging Biol. 2010;13:493-499.
18. Samano AK, Ohshima-Hosoyama S, Whitney TG, et al. Functional evaluation of therapeutic response for a mouse model of medulloblastoma. Transgenic Res. 2010;19:829-840.
19. Taniguchi E, Cho MJ, Arenkiel BR, et al. Bortezomib reverses a post-translational mechanism of tumorigenesis for patched1 haploinsufficiency in medulloblastoma. Pediatr Blood Cancer. 2009;53:136-144.
20. Griswold IJ, Shen LJ, La Rosee P, et al. Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis. Blood. 2004;104:2912-2918.
21. Samano AK, Ohshima-Hosoyama S, Whitney TG, et al. Functional evaluation of therapeutic response for a mouse model of medulloblastoma. Transgenic Res. 2010;19:829-840.
22. Hoch RV, Soriano P. Roles of PDGF in animal development. Development. 2003;130:4769-4784.
23. Klinghoffer RA, Hamilton TG, Hoch R, et al. An allelic series at the PDGFalphaR locus indicates unequal contributions of distinct signaling pathways during development. Dev Cell. 2002;2:103-113.
24. Thompson MC, Fuller C, Hogg TL, et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol. 2006;24:1924-1931.
25. Pfaff E, Remke M, Sturm D, et al. TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. J Clin Oncol. 2010;28:5188-5196.
26. Tabori U, Baskin B, Shago M, et al. Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. J Clin Oncol. 2010;28:1345-1350.
27. Mao J, Ligon KL, Rakhlin EY, et al. A novel somatic mouse model to survey tumorigenic potential applied to the Hedgehog pathway. Cancer Res. 2006;66:10171-10178.
28. Tabori U, Baskin B, Shago M, et al, Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. J Clin Oncol. 2010;28:1345-1350.